Penumbra recently presented a robust collection of pulmonary embolism (PE) data from six abstracts at the Transcatheter Cardiovascular Therapeutics Conference (TCT), expanding the evidence base for computer assisted vacuum thrombectomy (CAVT®) and, importantly, what recovery can look like. With up to 50% of PE survivors experiencing persistent functional limitations and compromised quality of life associated with post-PE syndrome, understanding the longer-term patient journey is increasingly important.1
CAVT technology is supported by an extensive and growing body of clinical evidence for mechanical thrombectomy in pulmonary embolism, including STRIKE-PE, and the STORM-PE randomized controlled trial. Together, these studies have advanced our understanding of not only the acute treatment of PE, but also how patients recover in the weeks and months that follow, with growing insights into right heart recovery, functional capacity, dyspnea, and quality of life.
The new analyses from STORM-PE and STRIKE-PE examine multiple dimensions of PE care, including right ventricular (RV) recovery, RV-pulmonary artery coupling, functional capacity, symptoms, and real-world activity captured through wearable technology. Collectively, these findings help connect improvements in cardiovascular function with outcomes that matter to patients over the long term, offering a more comprehensive view of the patient journey from intervention through recovery following acute PE.
“PE research is increasingly moving beyond what happens during the procedure to also examine how patients recover in the days and months that follow,” says James F. Benenati, MD, FSIR, chief medical officer at Penumbra. “These data help us better understand the relationship between restoring right heart function and meaningful outcomes such as exercise capacity, symptoms, and return to everyday activities. Building that evidence is critical as we continue working to improve both the immediate and longer-term trajectory for patients with pulmonary embolism.”
STORM-PE: Number Needed to Treat for Clinical and Functional Outcomes in STORM-PE
Presented by Rachel Rosovsky, MD, MPH, global co-principal investigator of STORM-PE RCT, hematology, Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School.
This analysis of the randomized STORM-PE trial quantified the benefits of CAVT plus anticoagulation compared with anticoagulation alone in 100 patients with intermediate-high-risk PE. Using number needed to treat (NNT), investigators found that for every three to five patients treated with CAVT plus anticoagulation rather than anticoagulation alone, one additional patient achieved improvement across select early physiologic parameters or 90-day functional outcomes.
Key findings include:
- NNT was 4 for an RV/LV ratio reduction >0.2 at 48 hours, achieved by 78.3% of CAVT patients versus 51.9% with anticoagulation alone (P =0.011).
- NNT was 3 for resolution of baseline tachycardia at 48 hours, achieved by 100% of CAVT patients versus 56.5% with anticoagulation alone (P =0.006).
- NNT was 5 for functional outcomes at 90 days, including achieving 100% predicted 6-minute walk distance and NYHA Class I. For NYHA Class I specifically, rates were 97.4% with CAVT versus 75.6% with anticoagulation alone (P =0.005).
STORM-PE: Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Presented by Robert Lookstein, MD, MSc, global co-principal investigator of the STORM-PE RCT, radiology and surgery, Icahn School of Medicine at Mount Sinai.
A STORM-PE subset analysis explored how clinical measures of functional recovery after acute intermediate-high risk pulmonary embolism translate to patients’ everyday activity. A cohort of patients from the randomized trial received wearable fitness watches at discharge to track real-world activity, including daily steps, walking bouts, peak step counts, and heart rate measures. Investigators evaluated associations between these wearable-derived measures and clinical-based 6-minute walk test (6MWT) distance assessed at 30- and 90-day follow-up. The analysis found a significant correlation between wearable-derived activity measures and the 6MWT at 30 days (more step-based activity was associated with longer 30-day 6MWT distance), as well as correlations between heart rate and 90-day 6MWT (larger differences between resting and peak heart rate were associated with longer 90-day 6MWT distance), providing initial evidence that consumer wearables may offer a complementary way to assess functional recovery after PE outside the clinic.
Key findings include:
- Total daily step count, walking bout length, number of walking bouts, walking bout duration and peak 10-minute step count were significantly correlated with 30-day 6MWT distance.
- Daily Δ heart rate was the strongest heart rate correlate of both step-based actigraphy and 90-day 6MWT distance, with a greater resting-to-peak heart rate difference associated with longer 6MWT distance.
- Wearable technology provides a complementary measure of functional recovery after PE.
STRIKE-PE: Sustained Recovery at One Year After Treatment with CAVT
Presented by Aleksander Araszkiewicz, MD, PhD, global co-principal investigator of the STRIKE-PE study, interventional cardiology, Poznan University of Medical Sciences.
This encore STRIKE-PE analysis evaluated 1,000 patients with acute PE treated with CAVT, of which 522 had completed one-year follow-up. The data demonstrated significant early reductions in RV strain as well as sustained improvements in symptoms, functional capacity, and quality of life through one year. The findings showed that improvements extended beyond the acute treatment period, with NYHA functional class returning to levels comparable to patients’ pre-PE status by 90 days and sustaining through one year, alongside continued gains in walking distance and relief of dyspnea.
Key findings include:
- Mean RV/LV ratio decreased 27.2%, from 1.38 at baseline to 0.97 at 48 hours (P <0.001), with a 48-hour major adverse event rate of 1.9%.
- Mean 6-minute walk distance increased from 366.2 at 90 days to 393.1 meters at one year (P <0.001).
- Median dyspnea-at-rest score improved from 5.7 at baseline to 0.8 at discharge and 0.3 at 90 days, sustaining at 0.3 through one year (P <0.001 from baseline to follow-up).
- QOL improved from baseline and reached population norm levels by 1 year (EQ-5D-5L: 0.413 to 0.821; population norm, 0.815).
STRIKE-PE: Improvement in Echocardiographic Parameters After CAVT for Pulmonary Embolism
Presented by Suhail Dohad, MD, interventional cardiology, Cedars-Sinai Medical Center.
This STRIKE-PE analysis evaluated outcomes in a subset of patients with at least one paired echocardiographic parameter measured at 48 hours. The echo analysis demonstrated significant improvement across multiple measures of right ventricular function and cardiopulmonary hemodynamics from baseline to 48-hour follow-up, underscoring the value of echocardiography for assessing patients before and after PE intervention.
Key findings include:
- TAPSE improved from 16.0 to 20.6 mm by 48 hours (P<0.001), above a normal value of >17 mm.
- The TAPSE/PASP ratio, a marker of RV-PA uncoupling, rose from 0.41 to 0.58 mm/mmHg by 48 hours, returning to a normal value.
- RVOT VTI increased from 9.3 to 12.6 cm and LVOT VTI increased from 14.1 to 18.9 cm (P <0.001 for both), providing additional evidence of improved cardiopulmonary hemodynamics at 48 hours.
STRIKE-PE: Correlation of Echocardiographic and CT-Derived Measures of RV Size and Function
Presented by Krishan Patel, MD, cardiology, Cedars-Sinai Medical Center.
This prospective, multicenter analysis examined how closely CT- and echocardiography-derived RV/LV ratios align in patients with acute PE after treatment with CAVT. Among 60 patients, researchers found a strong overall correlation between the two imaging modalities when measurements were tracked within patients over time. However, correlations varied by timepoint, highlighting the value of both modalities for longitudinal assessment while cautioning against directly substituting CT and echo RV/LV measurements.
Key findings include:
- RV/LV ratio decreased after thrombectomy from 1.43 at baseline to 0.98 at 48 hours by CT and from 1.16 at baseline to 0.89 at 48 hours by echocardiography, demonstrating substantial RV recovery regardless of imaging modality with similar standardized mean differences between modalities (-1.44 CT and -1.49 echo).
- Repeated measures correlation was strong between CT and echo RV/LV ratio change (r =0.75, P <0.001) showing that RV/LV ratio reduced regardless of modality within any given patient.
STRIKE-PE: Improved RV-PA Coupling Post Thrombectomy for Acute Pulmonary Embolism
Presented by Michael L. Chuang, MD, Cardiovascular Research Foundation, New York, New York, USA.
This STRIKE-PE substudy evaluated changes in right ventricular-pulmonary artery (RV-PA) coupling following treatment with CAVT. Among 89 patients, TAPSE/PASP ratio, an echocardiographic measure reflecting how well RV contractility accommodates pulmonary afterload, improved significantly at 48 hours. TAPSE/PASP ratio is an established measure of RV-PA coupling and short-term prognosis in acute PE, with lower values associated with worse outcomes.
Key findings include:
- TAPSE/PASP ratio increased significantly after CAVT, from a median of 0.41 at baseline to 0.58 mm/mmHg at 48 hours (P <0.001).
- 84.3% of patients had an increase in TAPSE/PASP ratio at 48 hours, suggesting improved RV-PA coupling (95% CI, 4.23–10.71; P <0.001).
Learn more about STORM-PE and STRIKE-PE.
Important Safety Information
Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/products/peripheral-thrombectomy-cavt/. The clinical results presented herein are for informational purposes only and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. For the complete Penumbra IFU Risk Summary Statements, visit: peninc.info/risk. Please contact your local Penumbra representative for more information. Copyright ©2026 Penumbra, Inc. All rights reserved. CAVT is a registered trademark or trademark of Penumbra, Inc. in the USA and other countries.
- Fountain JH, Peck TJ, Furfaro D. Sequelae of Acute Pulmonary Embolism: From Post-Pulmonary Embolism Functional Impairment to Chronic Thromboembolic Disease. Journal of Clinical Medicine. 2024; 13(21):6510. https://doi.org/10.3390/jcm13216510. ↩︎



